(ABOS) Acumen Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00509G2093

ABOS: Alzheimer's, Immunotherapy, Amyloid-Beta, Oligomers

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) is a clinical-stage biopharmaceutical company specializing in the development of targeted therapies for Alzheimers disease. The companys lead candidate, sabirnetug (ACU193), is a recombinant humanized immunoglobulin gamma 2 designed to target soluble amyloid-beta oligomers, which are implicated in the progression of Alzheimers. Sabirnetug has completed Phase I clinical trials, demonstrating its potential as an immunotherapy for this debilitating neurodegenerative disorder.

Acumen has established strategic partnerships to advance its pipeline. A license agreement with Lonza Sales AG ensures the manufacturing and commercialization of sabirnetug, while a collaboration with Halozyme, Inc. focuses on developing a subcutaneous formulation of the drug, enhancing patient accessibility. Incorporated in 1996 and headquartered in Charlottesville, Virginia, Acumen is positioned as a specialized player in the Alzheimers therapeutic landscape.

From a technical perspective, ABOS is currently trading at $1.23 with a 20-day average volume of 243,782 shares. The stock is below its 20-day SMA of $1.36 and 50-day SMA of $1.56, signaling near-term downward momentum. However, the 200-day SMA of $2.38 indicates longer-term weakness. The ATR of 0.11 reflects relatively low volatility.

Fundamentally, Acumens market cap stands at $76.90M with a price-to-book ratio of 0.35, suggesting modest valuation relative to book value. The price-to-sales ratio of 538.78 highlights investor expectations for future revenue growth despite current losses, as indicated by a return on equity of -37.60%.

3-Month Forecast Based on and , ABOS is expected to trade in a range of $1.00 to $1.50 over the next three months. The stock may face resistance at $1.36 (20-day SMA) and $1.56 (50-day SMA). Support levels are likely at $1.00, given the recent price action and low ATR of 0.11. The negative return on equity and lack of profitability may limit upside potential, while the high price-to-sales ratio reflects market optimism about its pipeline.

Additional Sources for ABOS Stock

ABOS Stock Overview

Market Cap in USD 75m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2021-07-01

ABOS Stock Ratings

Growth 5y -79.9%
Fundamental -
Dividend 0.0%
Rel. Strength Industry -66.7
Analysts 4.83/5
Fair Price Momentum 0.69 USD
Fair Price DCF -

ABOS Dividends

No Dividends Paid

ABOS Growth Ratios

Growth Correlation 3m -96.4%
Growth Correlation 12m -86.2%
Growth Correlation 5y -82.1%
CAGR 5y -52.64%
CAGR/Max DD 5y -0.56
Sharpe Ratio 12m -2.69
Alpha -90.27
Beta 2.60
Volatility 82.56%
Current Volume 155k
Average Volume 20d 188.1k
What is the price of ABOS stocks?
As of March 16, 2025, the stock is trading at USD 1.26 with a total of 154,985 shares traded.
Over the past week, the price has changed by +0.80%, over one month by -13.10%, over three months by -36.04% and over the past year by -69.19%.
Is Acumen Pharmaceuticals a good stock to buy?
No, based on ValueRay Analyses, Acumen Pharmaceuticals (NASDAQ:ABOS) is currently (March 2025) a stock to sell. It has a ValueRay Growth Rating of -79.94 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ABOS as of March 2025 is 0.69. This means that ABOS is currently overvalued and has a potential downside of -45.24%.
Is ABOS a buy, sell or hold?
Acumen Pharmaceuticals has received a consensus analysts rating of 4.83. Therefor, it is recommend to buy ABOS.
  • Strong Buy: 5
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for ABOS stock price target?
According to ValueRays Forecast Model, ABOS Acumen Pharmaceuticals will be worth about 0.8 in March 2026. The stock is currently trading at 1.26. This means that the stock has a potential downside of -38.1%.
Issuer Forecast Upside
Wallstreet Target Price 10.8 757.1%
Analysts Target Price 10.8 757.1%
ValueRay Target Price 0.8 -38.1%